SAMANTHA MARTIN: Open Payments
NPI 1699384628 · DERIDDER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 23 payments from 16 companies in 2025. Trend: 2023 $281 · 2024 $775 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 2 | $62 |
| ABBVIE INC. | 4 | $59 |
| Lilly USA, LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| BioMarin Pharmaceutical Inc. | 1 | $35 |
| Ardelyx, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| PFIZER INC. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
Products named: DUPIXENT, VOXZOGO 1.2mg, IBSRELA, QULIPTA, ZEPBOUND, CAPLYTA, REXULTI, NURTEC ODT.
Industry payments across LA — which companies pay providers there.
